Sadia Naz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sadia Naz has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Javed Anver Qureshi
Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54660, Pakistan
3 shared publications - Muzammal Mateen Azhar
Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan
3 shared publications - Shehwar Nadeem
Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54660, Pakistan
3 shared publications - Tahir Maqbool
Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan
3 shared publications - Awais Altaf
University of Lahore, Pakistan
2 shared publications - Inam Ullah
Centre for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54660, Pakistan
2 shared publications
Latest Publications
- Open Access
Apolipoprotein E Gene Variation in Pakistani Subjects with Type 2 Diabetes with and without Cardiovascular Complications
Background: Apolipoprotein E (APOE) gene polymorphism has been implicated in the pathogenesis of various metabolic disorders, including type 2 diabetes mellitus (T2DM). Type 2 diabetes mellitus (T2DM) is a major public health concern worldwide, including in Pakistan. Cardiovascular problems linked with T2DM have a significant impact on individuals and society. The goal of this study is to investigate the relationship between Apolipoprotein E (ApoE) genotypes, dyslipidemia, and cardiovascular complications such as ischemic heart disease (IHD) and stroke. Methods: This study was carried out on 260 subjects divided into controls and diabetics. The diabetics were further divided into four subgroups such as D1: diabetics without cardiovascular issues, D2: diabetics with heart disease, D3: diabetics with stroke, and D4: diabetics with both heart disease and stroke. Anthropometric parameters (age, BMI) and risk factors (smoking, diabetes duration, hypertension) were assessed in all groups. Serum levels of TC, TG, LDL, HDL, VLDL, creatinine, BSF, and HbA1c were also measured. Apolipoprotein E gene polymorphism was determined using PCR-RFLP. Results: Hypertension, BMI, and dyslipidemia are defined as elevated levels of total cholesterol, triglycerides, LDL, and VLDL, and decreased levels of HDL. Uncontrolled hyperglycemia (elevated fasting blood sugar and glycated hemoglobin) in T2DM was linked to vascular complications such as IHD and stroke. Hypertension was prevalent in 79.3% of the population. Stage 2 hypertension was more prevalent in all age groups. It was also noted that common genotypes in the Pakistani population are 3/3, 4/4, 2/3, and 3/4. The frequency of genotypes 3/4 and 2/3 is highest in diabetics with stroke. Genotype 3/3 is present frequently in diabetics with IHD/stroke and patients with both these complications. However, genotype 4/4 is most frequently found in diabetics with IHD. Conclusions: It is concluded that BMI, hypertension, hyperglycemia, atherosclerosis, and dyslipidemia are linked with cardiovascular complications of type 2 diabetes. Apolipoprotein E gene polymorphism is associated with cardiovascular disease in patients with diabetes by affecting the lipid profile.
Open AccessApolipoprotein E Gene Variation in Pakistani Subjects with Type 2 Diabetes with and without Cardiovascular Complications
Background: Apolipoprotein E (APOE) gene polymorphism has been implicated in the pathogenesis of various metabolic disorders, including type 2 diabetes mellitus (T2DM). Type 2 diabetes mellitus (T2DM) is a major public health concern worldwide, including in Pakistan. Cardiovascular problems linked with T2DM have a significant impact on individuals and society. The goal of this study is to investigate the relationship between Apolipoprotein E (ApoE) genotypes, dyslipidemia, and cardiovascular complications such as ischemic heart disease (IHD) and stroke. Methods: This study was carried out on 260 subjects divided into controls and diabetics. The diabetics were further divided into four subgroups such as D1: diabetics without cardiovascular issues, D2: diabetics with heart disease, D3: diabetics with stroke, and D4: diabetics with both heart disease and stroke. Anthropometric parameters (age, BMI) and risk factors (smoking, diabetes duration, hypertension) were assessed in all groups. Serum levels of TC, TG, LDL, HDL, VLDL, creatinine, BSF, and HbA1c were also measured. Apolipoprotein E gene polymorphism was determined using PCR-RFLP. Results: Hypertension, BMI, and dyslipidemia are defined as elevated levels of total cholesterol, triglycerides, LDL, and VLDL, and decreased levels of HDL. Uncontrolled hyperglycemia (elevated fasting blood sugar and glycated hemoglobin) in T2DM was linked to vascular complications such as IHD and stroke. Hypertension was prevalent in 79.3% of the population. Stage 2 hypertension was more prevalent in all age groups. It was also noted that common genotypes in the Pakistani population are 3/3, 4/4, 2/3, and 3/4. The frequency of genotypes 3/4 and 2/3 is highest in diabetics with stroke. Genotype 3/3 is present frequently in diabetics with IHD/stroke and patients with both these complications. However, genotype 4/4 is most frequently found in diabetics with IHD. Conclusions: It is concluded that BMI, hypertension, hyperglycemia, atherosclerosis, and dyslipidemia are linked with cardiovascular complications of type 2 diabetes. Apolipoprotein E gene polymorphism is associated with cardiovascular disease in patients with diabetes by affecting the lipid profile.
- Open Access
- 1 April 2024
- Published by MDPI AG in Preprints.org
Apolipoprotein E Gene Variation in Pakistani Type 2 Diabetic Subjects with and without Cardiovascular Complications
Background Apolipoprotein E (APOE) gene polymorphism has been implicated in the pathogenesis of various metabolic disorders, including type 2 diabetes mellitus (T2DM). Type 2 diabetes mellitus (T2DM) is a major public health concern worldwide, including in Pakistan. Cardiovascular problems linked with T2DM have a significant impact on people and society. The study's goal is to investigate the relationship between Apolipoprotein E (ApoE) genotypes, lipid profiles, and cardiovascular complications such as ischemic heart disease (IHD) and stroke. Methods: This study was carried out on 260 subjects, divided into control D1: Diabetics without cardiovascular issues. D2: Diabetics with heart disease. D3: Diabetics with stroke. D4: Diabetics with both heart disease and stroke. Anthropometric parameters (age, BMI) and risk factors (smoking, diabetes duration, hypertension) were assessed in all groups. Serum levels of TC, TG, LDL, HDL, VLDL, creatinine, BSF, and HbA1c were measured. Apolipoprotein E gene polymorphism was determined using PCR-RFLP. Results: Hypertension, BMI, and dyslipidemia, defined as elevated levels of total cholesterol, triglycerides, LDL, HDL, and VLDL, as well as uncontrolled hyperglycemia (elevated fasting blood sugar and glycated hemoglobin) in T2DM, were linked to vascular complications such as IHD and stroke. Hypertension was prevalent in 75.4% of the population, with greater rates among the elderly. Stage 2 hypertension was more prevalent in all age groups. Apolipoprotein E gene polymorphism was discovered, with genotypes 3/3, 4/4, 2/3, and 3/4 being the most prevalent. Genotype 3/4 was more common in diabetics who had IHD/stroke or both problems, whereas genotype 2/3 was linked to DM and stroke. Conclusion: It is concluded that BMI, hypertension, hyperglycemia, atherosclerosis, and dyslipidemia are linked with cardiovascular complications of type 2 diabetes. Apolipoprotein E gene polymorphism is associated with cardiovascular disease in diabetic patients by affecting the lipid profile.
- 1 April 2024
- Published by MDPI AG in Preprints.org
Open AccessApolipoprotein E Gene Variation in Pakistani Type 2 Diabetic Subjects with and without Cardiovascular Complications
Background Apolipoprotein E (APOE) gene polymorphism has been implicated in the pathogenesis of various metabolic disorders, including type 2 diabetes mellitus (T2DM). Type 2 diabetes mellitus (T2DM) is a major public health concern worldwide, including in Pakistan. Cardiovascular problems linked with T2DM have a significant impact on people and society. The study's goal is to investigate the relationship between Apolipoprotein E (ApoE) genotypes, lipid profiles, and cardiovascular complications such as ischemic heart disease (IHD) and stroke. Methods: This study was carried out on 260 subjects, divided into control D1: Diabetics without cardiovascular issues. D2: Diabetics with heart disease. D3: Diabetics with stroke. D4: Diabetics with both heart disease and stroke. Anthropometric parameters (age, BMI) and risk factors (smoking, diabetes duration, hypertension) were assessed in all groups. Serum levels of TC, TG, LDL, HDL, VLDL, creatinine, BSF, and HbA1c were measured. Apolipoprotein E gene polymorphism was determined using PCR-RFLP. Results: Hypertension, BMI, and dyslipidemia, defined as elevated levels of total cholesterol, triglycerides, LDL, HDL, and VLDL, as well as uncontrolled hyperglycemia (elevated fasting blood sugar and glycated hemoglobin) in T2DM, were linked to vascular complications such as IHD and stroke. Hypertension was prevalent in 75.4% of the population, with greater rates among the elderly. Stage 2 hypertension was more prevalent in all age groups. Apolipoprotein E gene polymorphism was discovered, with genotypes 3/3, 4/4, 2/3, and 3/4 being the most prevalent. Genotype 3/4 was more common in diabetics who had IHD/stroke or both problems, whereas genotype 2/3 was linked to DM and stroke. Conclusion: It is concluded that BMI, hypertension, hyperglycemia, atherosclerosis, and dyslipidemia are linked with cardiovascular complications of type 2 diabetes. Apolipoprotein E gene polymorphism is associated with cardiovascular disease in diabetic patients by affecting the lipid profile.
- Open Access
- 1 January 2024
- Published by Green Publication
- Vol. 31 (3) , 325-337
THERAPEUTIC INSIGHTS OF VITAMIN D IN THE MANAGEMENT OF TYPE 2 DIABETIC NEUROPATHY
Background: Diabetes mellitus is derived from the Greek term diabetes, meaning siphon - to pass through, and the Latin word mellitus, meaning sweet. The most common consequence is neuropathy, namely distal symmetric polyneuropathy (referred to as diabetic neuropathy in this primer). Diabetic neuropathy is a loss of sensory function that begins distally in the lower limbs and is accompanied by discomfort and significant morbidity. Over time, at least 50% of diabetics develop diabetic neuropathy. The study aimed to identify the impact of oxidative markers (glutathione (GSH), advanced oxidation protein products (AOPP), advanced glycation end products (AGEs), malondialdehyde (MDA), and inflammatory biomarkers (interleukin-6, IL-6, TNF-α, and myeloperoxidase (MPO)) on the development of diabetic neuropathy along with routinely used biochemical parameters. Materials and Method: This was a case-control study. All the selected patients were screened and enrolled by convenient non-probability sampling technique at the social security hospital Lahore. Written Informed consent was obtained before enrollment of the study subjects. A total of 150 patients enrolled in the study, and they were divided into three groups, 50 subjects with type 2 diabetic neuropathy taking oral antidiabetics only and 50 diagnosed diabetic neuropathy (DN) subjects taking adjunct oral vitamin D therapy, 50 healthy individuals as a control group. Five mL of venous blood sample was taken from the antecubital vein of each participant. Statistical analysis was performed by GraphPad. The results of all variables were evaluated by using one-way ANOVA. Results: The mean value of biochemical parameters (WBCs, platelets, HbA1c, BSF, triglycerides, LDL, HDL, serum creatinine, and liver function tests, were increased in diabetics with neuropathy compared to the control and treated group. There was a significant improvement in these parameters after vitamin D therapy, the mean values of MDA, AGE, and AOPPs in type 2 diabetics with neuropathy were significantly increased compared to the control group and a significant decrease was noticed after vitamin D supplementation in the vitamin D group. GSH level was decreased in type 2 diabetics with DPN patients as compared to the control group. A significant increase in GSH was noticed in the vitamin D group. In addition, IL-6, TNFα, and MPO levels were also increased in the case of diabetic neuropathy as compared to controls. However, a significant decrease in the levels was seen in the vitamin D group. Conclusions: ROS-mediated injuries in type 2 diabetics with neuropathy can be prevented by the restoration of an antioxidant defense system, through the administration of antioxidant agents and micronutrients like vitamin D as an adjunct therapy along with antidiabetics drugs insulin/oral antidiabetics. Moreover, increased levels of inflammatory mediators are responsible for enhancing inflammation in patients with diabetic neuropathy. Vitamin D helps to decrease the levels of inflammatory biomarkers in subjects with diabetic neuropathy.
- 1 January 2024
- Published by Green Publication
- Vol. 31 (3) , 325-337
Open AccessTHERAPEUTIC INSIGHTS OF VITAMIN D IN THE MANAGEMENT OF TYPE 2 DIABETIC NEUROPATHY
Background: Diabetes mellitus is derived from the Greek term diabetes, meaning siphon - to pass through, and the Latin word mellitus, meaning sweet. The most common consequence is neuropathy, namely distal symmetric polyneuropathy (referred to as diabetic neuropathy in this primer). Diabetic neuropathy is a loss of sensory function that begins distally in the lower limbs and is accompanied by discomfort and significant morbidity. Over time, at least 50% of diabetics develop diabetic neuropathy. The study aimed to identify the impact of oxidative markers (glutathione (GSH), advanced oxidation protein products (AOPP), advanced glycation end products (AGEs), malondialdehyde (MDA), and inflammatory biomarkers (interleukin-6, IL-6, TNF-α, and myeloperoxidase (MPO)) on the development of diabetic neuropathy along with routinely used biochemical parameters. Materials and Method: This was a case-control study. All the selected patients were screened and enrolled by convenient non-probability sampling technique at the social security hospital Lahore. Written Informed consent was obtained before enrollment of the study subjects. A total of 150 patients enrolled in the study, and they were divided into three groups, 50 subjects with type 2 diabetic neuropathy taking oral antidiabetics only and 50 diagnosed diabetic neuropathy (DN) subjects taking adjunct oral vitamin D therapy, 50 healthy individuals as a control group. Five mL of venous blood sample was taken from the antecubital vein of each participant. Statistical analysis was performed by GraphPad. The results of all variables were evaluated by using one-way ANOVA. Results: The mean value of biochemical parameters (WBCs, platelets, HbA1c, BSF, triglycerides, LDL, HDL, serum creatinine, and liver function tests, were increased in diabetics with neuropathy compared to the control and treated group. There was a significant improvement in these parameters after vitamin D therapy, the mean values of MDA, AGE, and AOPPs in type 2 diabetics with neuropathy were significantly increased compared to the control group and a significant decrease was noticed after vitamin D supplementation in the vitamin D group. GSH level was decreased in type 2 diabetics with DPN patients as compared to the control group. A significant increase in GSH was noticed in the vitamin D group. In addition, IL-6, TNFα, and MPO levels were also increased in the case of diabetic neuropathy as compared to controls. However, a significant decrease in the levels was seen in the vitamin D group. Conclusions: ROS-mediated injuries in type 2 diabetics with neuropathy can be prevented by the restoration of an antioxidant defense system, through the administration of antioxidant agents and micronutrients like vitamin D as an adjunct therapy along with antidiabetics drugs insulin/oral antidiabetics. Moreover, increased levels of inflammatory mediators are responsible for enhancing inflammation in patients with diabetic neuropathy. Vitamin D helps to decrease the levels of inflammatory biomarkers in subjects with diabetic neuropathy.